

BIOCON GROUP

FINANCIALS

9M FY 2008 vs 9M FY 2007

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT

(Rs. crores)

Particulars	9 M FY 2008	9 M FY 2007	Full Year ended March 31, 2007
<u>INCOME</u>			
Biopharmaceuticals	612	541	741
Enzymes	46	76	109
Contract research	129	90	136
Total Sales	787	707	986
Other income	24	3	4
Total Income / Revenues	811	710	990
<u>EXPENDITURE</u>			
Material & Power Costs	383	373	451
Staff costs	88	65	91
Manufacturing, staff & other exps	100	72	160
PBDIT /EBIDTA	240	200	288
Interest and finance charges	8	5	10
PBDT	232	195	278
Depreciation	69	47	67
PBT	163	148	211
Taxes	7	11	17
PROFIT FOR THE PERIOD	156	137	194
Add/(less): Minority interest	4	3	6
Profit Before Exceptional Items	160	140	200
Exceptional Items (Net of Tax)	239	-	-
NET PROFIT (PAT)	399	140	200
EPS on issued capital (Rs)- Before Exceptional Item	16.0	14.0	20.0
EPS on issued capital (Rs)- After Exceptional Item	39.9	14.0	20.0

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		(Rs. crores)
Particulars	As at 31-Dec-07	As at 31-Mar-07
<u>SOURCES OF FUNDS</u>		
Share Capital	50	50
Reserves & Surplus	1,428	1,019
Total Shareholder's Funds	1,478	1,069
Minority interest	(5)	(1)
Deferred Tax Liability	44	45
Secured Loans	26	74
Unsecured Loans	118	113
Total Loan Funds	144	187
Total	1,661	1,300
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	1,007	915
Intangible Assets	28	51
Investments	391	79
Inventories	180	161
Sundry debtors	264	307
Cash and bank balances	12	9
Loans and advances	56	53
Total Current Assets, Loans & Advances	512	530
Less: Current liabilities and provisions	277	275
Net Current assets	235	255
Total	1,661	1,300

BIOCON LIMITED (CONSOLIDATED)		
STATEMENT OF CASH FLOWS		(Rs. crores)
Particulars	Nine Month Period Ended December 31, 2007	Full Year ended March 31, 2007
<u>I. Cash Flow from Operating Activities</u>		
Net profit before tax	470	211
Less/Add: non-cash items/ items required separately		
Depreciation	70	67
Exceptional Income considered separately	(308)	
Others	10	15
Changes in working capital and other provisions	34	(128)
Cash generated from operations	276	165
Tax paid (net of refunds)	(58)	(13)
Net Cash provided by operating activities	218	152
<u>II. Cash Flow from Investing Activities</u>		
Fixed Assets	(155)	(172)
Exceptional Income, net	330	
Intangible Assets	(22)	
Change in minority Interest	4	2
Interest / dividend received	12	2
Investments	(312)	(31)
Net cash used for investing activities	(143)	(199)
<u>III. Cash Flows from Financing Activities</u>		
Borrowings and other financing activities	(80)	51
Net Cash provided/(used) for financing activities	(80)	51
<u>IV. Net Change in Cash and Cash Equivalents (I+II+III)</u>	(5)	4
<u>V. Cash & Cash Eq. at the beginning of the year</u>	9	2
<u>VI. Cash and Cash Equivalents of the ESOP Trust acquired during the year</u>	8	3
<u>VII. Cash and Cash Eq. at the end of the year (IV+V+VI)</u>	12	9